Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar:134:102905.
doi: 10.1016/j.ctrv.2025.102905. Epub 2025 Feb 20.

BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives

Stefania Napolitano  1 , Davide Ciardiello  2 , Eleonora Cioli  3 , Erika Martinelli  3 , Teresa Troiani  3 , Maria Giulia Zampino  2 , Nicola Fazio  2 , Ferdinando De Vita  3 , Fortunato Ciardiello  3 , Giulia Martini  3
Affiliations
Free article
Review

BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives

Stefania Napolitano et al. Cancer Treat Rev. 2025 Mar.
Free article

Abstract

Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis. The evolution of molecular profiling and the implementation of next generation sequencing in the evaluation of a patient with BRAF-mutated mCRC has currently led to the discovery of actionable alterations. Targeting multiple pathways of resistance in BRAF-mutated mCRC may be the most efficacious route. Then, over a short period of time, the treatment landscape BRAF-mutated mCRC patients has shifted dramatically. Finally, novel treatment strategies are available. This review will discuss on currently approved treatments for BRAF V600E mutated mCRC and will try and portray the changing landscape in this setting in the era of targeted molecular therapy.

Keywords: BRAFV600E CRC; Cetuximab; Encorafenib; Immunotherapy; Targeted agents.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [SN reported receiving personal fees from Novartis, Merck KgA, Pierre Fabre and a travel grant from Novartis outside the submitted work. DC reported receiving travel support from Merck KgA, Sanofi, and BMS and advisory board for Bayer outside the submitted work. EM reported receiving personal fees and advisory board for AstraZeneca, ESMO, Merck-Serono, Roche, Servier and Takeda outside the submitted work. TT received travel grants from AstraZeneca and Pierre Fabre and is an advisory board member for AstraZeneca, Bayer, Amgen, Merck, Roche, Sanofi, Servier, and Pierre Fabre. NF: reported receiving research funds from and serving on an advisory board for Merck outside the submitted work. FDV: reports consulting fees from Daiichi Sankyo and payment or honoraria from Servier, Amgen, Roche, Eli Lilly, Daiichi Sankyo, and AstraZeneca. FC received institutional research grants from Amgen, Merck KGaA, Merck Sharp & Dohme, Pfizer, Pierre Fabre, Roche, and Servier; and service on advisory boards for Bayer, Merck KGaA, Merck Sharp & Dohme, Pierre Fabre, Roche, and Servier outside the submitted work. GM reports receiving honoraria from Servier, Incyte, and Pierre Fabre outside the submitted work. All other authors have declared no conflicts of interest.].

MeSH terms

Substances